Novel Cardiac Myosin Inhibitors Targeting Obstructive Hypertrophic Cardiomyopathy's Root Cause


Anjali Tiku Owens, MD, examines the unmet needs in treating obstructive hypertrophic cardiomyopathy (oHCM) and explores how novel Cardiac Myosin inhibitors (CMIs) address the root cause of the condition.

  1. The treatment of obstructive hypertrophic cardiomyopathy (oHCM) has a high level of unmet needs, can you discuss these with us?
  • How do novel cardiac myosin inhibitors (CMIs) target the underlying cause of oHCM?

2. What has the impact of CMI’s been on the management of oHCM?

  • Complements (first line) standard of care
  • Addresses the root cause of oHCM
  • Narrowing the substantial gap between effective medical therapy and the more definitive invasive treatments like alcohol septal ablation and surgical myectomy.
Related Videos
A panel of 5 cardiovascular experts
Ghada Bourjeily, MD: Research Gaps on Sleep Issues During Pregnancy
John Winkelman, MD, PhD: When to Use Low-Dose Opioids for Restless Legs Syndrome
Bhanu Prakash Kolla, MBBS, MD: Treating Sleep with Psychiatric Illness
Jennifer Martin, PhD: Boosting CPAP Adherence in Women with Sleep Apnea
Video 2 -  4 KOLs are featured in, "Educating Primary Care Clinicians on Outpatient HE Management and Ammonia Testing"
Video 1 - 4 KOLs are featured in, "Exploring the Impact of Hepatic Encephalopathy on Patients and Their Families "
© 2024 MJH Life Sciences

All rights reserved.